The DOI matches its OpenAlex record; 14 of the 14 references it cites were found in a registry or an index.
Anticonvulsant Hypersensitivity Syndrome
Abstract
Anticonvulsant hypersensitivity syndrome is a potentially fatal drug reaction with cutaneous and systemic reactions (incidence, one in 1000 to one in 10,000 exposures) to the arene oxide-producing anticonvulsants--phenytoin, carbamazepine, and phenobarbital sodium. In most cases, the hallmark features of fever, rash, and lymphadenopathy are accompanied by multiorgan-system abnormalities. Fatal outcomes are most often associated with liver failure. Recognition of the syndrome, which may have variable presentations, is the key to prompt discontinuation of the drug, close monitoring, and management. The reaction may be genetically determined, and siblings of patients with anticonvulsive hypersensitivity syndrome may be at increased risk of developing this syndrome. The timely recognition of anticonvulsant hypersensitivity syndrome is important, because accurate diagnosis avoids potentially fatal reexposure and affects subsequent anticonvulsant treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk.
Shear, N. H., & Spielberg, S. P. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113798 · Cited by 687
Saltzstein, S. L., & Ackerman, L. V. (1959) · Cancer · doi:10.1002/1097-0142(195901/02)12:1<164::aid-cncr2820120122>3.0.co;2-y · Cited by 327
Predisposition to Phenytoin Hepatotoxicity Assessed in Vitro
Spielberg, S. P., Gordon, G. B., Blake, D. A., Goldstein, D. A., & Herlong, H. F. (1981) · New England Journal of Medicine · doi:10.1056/nejm198109243051302 · Cited by 234
Familial occurrence of hypersensitivity to phenytoin
Gennis, M. A., Vemuri, R., Burns, E. A., Hill, J. V., Miller, M. A., & Spielberg, S. P. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90216-k · Cited by 151
Anticonvulsant toxicity in vitro: possible role of arene oxides.
Spielberg, S. P., Gordon, G., Blake, D. A., Mellits, E. D., & Bross, D. (1981) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32544-9 · Cited by 139
Haruda, F. D. (1979) · Neurology · doi:10.1212/wnl.29.11.1480 · Cited by 121
Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro
Gerson, W., Fine, D., Sp, S., & Sensenbrenner, L. (1983) · Blood · doi:10.1182/blood.v61.5.889.889 · Cited by 103
Cutaneous and immunologic reactions to phenytoin
Silverman, A. K., Fairley, J. A., & Wong, R. (1988) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(88)70096-1 · Cited by 98
Pirmohamed, M., Graham, A., Roberts, P. E., Smith, D., Chadwick, D. W., Breckenridge, A., & Park, B. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb03983.x · Cited by 90
Parker, W. A., & Shearer, C. A. (1979) · Neurology · doi:10.1212/wnl.29.2.175 · Cited by 68
Cited by
Kardaun, S. H., Sekula, P., Valeyrie-Allanore, L., Liss, Y., Chu, C. Y., Creamer, D., Sidoroff, A., Naldi, L., Mockenhaupt, M., Roujeau, J. C., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12501 · Cited by 1,010
Bocquet, H., Bagot, M., & Roujeau, J. C. (1996) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/s1085-5629(96)80038-1 · Cited by 964
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions
Hung, S.-I., Chung, W.-H., Jee, S.-H., Chen, W.-C., Chang, Y.-T., Lee, W.-R., Hu, S.-L., Wu, M.-T., Chen, G.-S., Wong, T.-W., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000199500.46842.4a · Cited by 680
Husain, Z., Reddy, B. Y., & Schwartz, R. A. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.01.033 · Cited by 489
Shiohara, T., Inaoka, M., & Kano, Y. (2006) · Allergology International · doi:10.2332/allergolint.55.1 · Cited by 485
Locharernkul, C., Loplumlert, J., Limotai, C., Korkij, W., Desudchit, T., Tongkobpetch, S., Kangwanshiratada, O., Hirankarn, N., Suphapeetiporn, K., & Shotelersuk, V. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01719.x · Cited by 482
Peyrière, H., Dereure, O., Breton, H., Demoly, P., Cociglio, M., Blayac, J.-P., Hillaire-Buys, D., & the Network of the French Pharmacovigilance Centers (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07284.x · Cited by 348
Tohyama, M., Hashimoto, K., Yasukawa, M., Kimura, H., Horikawa, T., Nakajima, K., Urano, Y., Matsumoto, K., Iijima, M., & Shear, N. H. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08167.x · Cited by 341
Rash in Multicenter Trials of Lamotrigine in Mood Disorders: Clinical Relevance and Management
Calabrese, J. R., Sullivan, J. R., Bowden, C. L., Suppes, T., Goldberg, J. F., Sachs, G. S., Shelton, M. D., Goodwin, F. K., Frye, M. A., & Kusumakar, V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1110 · Cited by 334
Idiosyncratic drug reactions: the reactive metabolite syndromes
Knowles, S. R., Uetrecht, J., & Shear, N. H. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03137-8 · Cited by 331
Idiosyncratic Adverse Drug Reactions: Current Concepts
Uetrecht, J., & Naisbitt, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007450 · Cited by 310
Epoxide hydrolases: biochemistry and molecular biology
Fretland, A. J., & Omiecinski, C. J. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00197-6 · Cited by 307
Idiosyncratic Drug Reactions: Current Understanding
Uetrecht, J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105150 · Cited by 304
Anticonvulsant Hypersensitivity Syndrome: Incidence, Prevention and Management
Knowles, S. R., Shapiro, L. E., & Shear, N. H. (1999) · Drug Safety · doi:10.2165/00002018-199921060-00005 · Cited by 303
Management of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS Syndrome): An Update
Tas, S., & Simonart, T. (2003) · Dermatology · doi:10.1159/000069956 · Cited by 292
The clinical impact of pharmacogenetics on the treatment of epilepsy
Löscher, W., Klotz, U., Zimprich, F., & Schmidt, D. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01716.x · Cited by 281
Drug-induced liver injury: Summary of a single topic clinical research conference
Watkins, P. B., & Seeff, L. B. (2006) · Hepatology · doi:10.1002/hep.21095 · Cited by 279
Central role of mitochondria in drug-induced liver injury
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277
Takahashi, R., Kano, Y., Yamazaki, Y., Kimishima, M., Mizukawa, Y., & Shiohara, T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804002 · Cited by 276
Svensson, C. K., Cowen, E. W., & Gaspari, A. A. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01501-1 · Cited by 267
Tohyama, M., Yahata, Y., Yasukawa, M., Inagi, R., Urano, Y., Yamanishi, K., & Hashimoto, K. (1998) · Archives of Dermatology · doi:10.1001/archderm.134.9.1113 · Cited by 266
HLA-B Locus in Caucasian Patients with Carbamazepine hypersensitivity
Alfirevic, A., Jorgensen, A. L., Williamson, P. R., Chadwick, D. W., Park, B. K., & Pirmohamed, M. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.6.813 · Cited by 264
Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease
Castiella, A. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i4.160 · Cited by 131
Metadata
- Authors
- Vittorio, C. C.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association
- Published
- 1995-11-27
- Volume
- 155
- Issue
- 21
- Pages
- 2285-2285
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W1965303172
- Cited by
- 436
- References
- 14
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.